The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Implementation of a proactive outreach program to patients with gastrointestinal malignancies starting new chemotherapy regimens.
 
Dina Ioffe
No Relationships to Disclose
 
Peter D. Whooley
No Relationships to Disclose
 
Marie Riehl
No Relationships to Disclose
 
Tara DelGrippo
No Relationships to Disclose
 
James Helstrom
No Relationships to Disclose
 
Martin Joseph Edelman
Stock and Other Ownership Interests - Biomarker Strategies
Consulting or Advisory Role - e-doctor healthcare reviews; Flame Biosciences; Kanaph Therapeutics; Precision Oncology; Proventus Group; Sanofi/Regeneron; WindMIL
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Nektar (Inst); United Therapeutics (Inst); Windmil (Inst)
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - AstraZeneca/MedImmune; Boehringer Ingelheim; Seagen; Takeda
 
Efrat Dotan
Consulting or Advisory Role - Basilea Pharmaceutical; Helsinn Therapeutics; Incyte; QED Therapeutics
Research Funding - AstraZeneca (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); Relay Therapeutics (Inst); Zymeworks (Inst)
 
Jessica R Bauman
Consulting or Advisory Role - BeiGene; Blueprint Medicines; Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Turning Point Therapeutics